CMS subsidiary Dermavon gets China approval for additional Lumirix indication
CMS says its subsidiary Dermavon has received approval in China for an additional indication of Lumirix(R) for atopic dermatitis (AD).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
CMS subsidiary Dermavon gets China approval for Lumirix atopic dermatitis
CMS says its subsidiary Dermavon has received approval in China for Lumirix for an additional indication of atopic dermatitis.